01 October 2016

BSH has supported a letter to the European Medicines Agency's Committee for Human Medicinal Products (CHMP) providing more information on the importance of Ninlaro® (ixazomib) as a treatment option for myeloma patients.

The letter, created with Myeloma UK, Myeloma Patients Europe and other European organisations, supports an appeal against the CHMP's negative recommendation of Ninlaro in May.

You can read the letter online now.